Vistagen Therapeutics, Inc. 8-K Filing

Ticker: VTGN · Form: 8-K · Filed: Dec 6, 2024 · CIK: 1411685

Vistagen Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyVistagen Therapeutics, Inc. (VTGN)
Form Type8-K
Filed DateDec 6, 2024
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

FAQ

What type of filing is this?

This is a 8-K filing submitted by Vistagen Therapeutics, Inc. (ticker: VTGN) to the SEC on Dec 6, 2024.

What are the key financial figures in this filing?

Key dollar amounts include: $0.001 (ich registered Common Stock, par value $0.001 per share VTGN Nasdaq Capital Market).

How long is this filing?

Vistagen Therapeutics, Inc.'s 8-K filing is 2 pages with approximately 511 words. Estimated reading time is 2 minutes.

Where can I view the full 8-K filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 511 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-12-06 16:49:35

Key Financial Figures

  • $0.001 — ich registered Common Stock, par value $0.001 per share VTGN Nasdaq Capital Market

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On December 6, 2024, Vistagen Therapeutics, Inc. began utilizing a new corporate presentation, a copy of which is attached to this Current Report on Form 8-K as Exhibit 99.1. Disclaimer . The information in this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), nor shall Exhibit 99.1 filed herewith be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits . (d) Exhibits Index Exhibit No. Description 99.1 Vistagen Therapeutics, Inc. Corporate Presentation, dated December 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

Signatures

Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Vistagen Therapeutics, Inc. Date: December 6, 2024 By: /s/ Shawn K. Singh Shawn K. Singh Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.